Hyperpolarized (13)C Pyruvate MRI/MRS for Characterizing Splenic Metabolism in Advanced Diffuse Large B-Cell Lymphoma: A Pilot Study
Hyperpolarized [1-13C]pyruvate MRI/MRS was completed in all five patients, with kinetic analysis feasible in four.
This study demonstrates that hyperpolarized (13)C pyruvate MRI/MRS can be safely performed in patients with advanced diffuse large B-cell lymphoma (DLBCL) and that the technique may capture splenic metabolic activity that correlates with FDG-PET/CT metrics. The findings justify larger longitudinal studies to evaluate the method as a potential biomarker for disease burden and therapeutic response.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers